Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230902081> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4230902081 endingPage "64" @default.
- W4230902081 startingPage "55" @default.
- W4230902081 abstract "Three hundred and fifteen patients were randomly allocated to treatment for six months with bisoprolol 5 or 10 mg day−1 or atenolol, 50 mg day−1, in a double-blind, double-dummy parallel group, international multicentre study. Two hundred and ninety-two (175 men and 117 women) were eligible for statistical follow-up. Their mean age was 52.6 years (range 28–70). All patients had a supine diastolic blood pressure of 95–120 mmHg on two occasions during the four weeks of placebo treatment. Twenty-four patients ended the study prematurely and a further 19 had their regimes changed because of an insufficient effect. The reasons for drop-out were similar in the three treatment groups. Thus, 249 patients continued to receive the treatment they were allocated to, with 80, 83 and 86 patients in the three respective groups. The sex and age distributions and the number of previously treated hypertensives were similar in the three groups. At the end of placebo treatment the supine blood pressures in the three groups (bisoprolol 5 or 10 mg day−1 or atenolol 50 mg day−1, respectively) were 163.9/102.5, 157.4/101.8 and 160.0/102.2 mm Hg, respectively. The systolic blood pressure was higher (P>0.05) in the group receiving bisoprolol 5 mg day−1 than in the 10 mg day−1 group. After 26 weeks of treatment the supine blood pressures in the three groups were 150.6/90.8, 142.0/89.1 and 148.6/91.7 mmHg, respectively. The largest estimated difference in blood pressure reduction was 4.6/2.3 mmHg between the group receiving bisoprolol 10 mg day−1 and the group receiving atenolol 50 mg day−1. A reduction in mean blood pressure of ≥ 10 mmHg was noted in 66% of the patients in the bisoprolol group (10mg day −1), in the other groups 66 and 59%, n.s. Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension. A daily dose of 5mg seems recommendable for the majority of hypertensive patients and seems equipotent with 50 mg day−1 of atenolol in the present study." @default.
- W4230902081 created "2022-05-11" @default.
- W4230902081 creator A5004243459 @default.
- W4230902081 creator A5028303302 @default.
- W4230902081 creator A5029823910 @default.
- W4230902081 creator A5044118141 @default.
- W4230902081 creator A5068821984 @default.
- W4230902081 date "1987-12-02" @default.
- W4230902081 modified "2023-09-26" @default.
- W4230902081 title "Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: A double-blind, parallel group international multicentre study" @default.
- W4230902081 doi "https://doi.org/10.1093/eurheartj/8.suppl_m.55" @default.
- W4230902081 hasPublicationYear "1987" @default.
- W4230902081 type Work @default.
- W4230902081 citedByCount "0" @default.
- W4230902081 crossrefType "journal-article" @default.
- W4230902081 hasAuthorship W4230902081A5004243459 @default.
- W4230902081 hasAuthorship W4230902081A5028303302 @default.
- W4230902081 hasAuthorship W4230902081A5029823910 @default.
- W4230902081 hasAuthorship W4230902081A5044118141 @default.
- W4230902081 hasAuthorship W4230902081A5068821984 @default.
- W4230902081 hasConcept C125567185 @default.
- W4230902081 hasConcept C126322002 @default.
- W4230902081 hasConcept C141071460 @default.
- W4230902081 hasConcept C142724271 @default.
- W4230902081 hasConcept C204787440 @default.
- W4230902081 hasConcept C27081682 @default.
- W4230902081 hasConcept C2776525901 @default.
- W4230902081 hasConcept C2777097880 @default.
- W4230902081 hasConcept C2779670145 @default.
- W4230902081 hasConcept C42219234 @default.
- W4230902081 hasConcept C71924100 @default.
- W4230902081 hasConcept C84393581 @default.
- W4230902081 hasConceptScore W4230902081C125567185 @default.
- W4230902081 hasConceptScore W4230902081C126322002 @default.
- W4230902081 hasConceptScore W4230902081C141071460 @default.
- W4230902081 hasConceptScore W4230902081C142724271 @default.
- W4230902081 hasConceptScore W4230902081C204787440 @default.
- W4230902081 hasConceptScore W4230902081C27081682 @default.
- W4230902081 hasConceptScore W4230902081C2776525901 @default.
- W4230902081 hasConceptScore W4230902081C2777097880 @default.
- W4230902081 hasConceptScore W4230902081C2779670145 @default.
- W4230902081 hasConceptScore W4230902081C42219234 @default.
- W4230902081 hasConceptScore W4230902081C71924100 @default.
- W4230902081 hasConceptScore W4230902081C84393581 @default.
- W4230902081 hasIssue "suppl M" @default.
- W4230902081 hasLocation W42309020811 @default.
- W4230902081 hasOpenAccess W4230902081 @default.
- W4230902081 hasPrimaryLocation W42309020811 @default.
- W4230902081 hasRelatedWork W1970254411 @default.
- W4230902081 hasRelatedWork W1974142229 @default.
- W4230902081 hasRelatedWork W2021488331 @default.
- W4230902081 hasRelatedWork W2032411983 @default.
- W4230902081 hasRelatedWork W2066617347 @default.
- W4230902081 hasRelatedWork W2071554631 @default.
- W4230902081 hasRelatedWork W2114876772 @default.
- W4230902081 hasRelatedWork W2119301592 @default.
- W4230902081 hasRelatedWork W2130206139 @default.
- W4230902081 hasRelatedWork W2150884935 @default.
- W4230902081 hasVolume "8" @default.
- W4230902081 isParatext "false" @default.
- W4230902081 isRetracted "false" @default.
- W4230902081 workType "article" @default.